查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011535

腦膜炎雙球菌疫苗市場：全球市場預測（依疫苗類型、年齡層、劑型、通路、最終用戶和適應症分類）－2026-2032年

Meningococcal Vaccines Market by Vaccine Type, Age Group, Formulation, Distribution Channel, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦膜炎雙球菌疫苗市值將達到 66 億美元，到 2026 年將成長至 71.6 億美元，到 2032 年將達到 137.4 億美元，複合年成長率為 11.02%。

主要市場統計數據
基準年 2025 66億美元
預計年份：2026年 71.6億美元
預測年份 2032 137.4億美元
複合年成長率 (%) 11.02%

公共衛生、臨床和技術趨勢正在重塑腦膜炎雙球菌疫苗利益相關人員的策略重點。

全球腦膜炎雙球菌疫苗格局正處於關鍵時刻，其發展受到抗原設計進步、免疫接種建議不斷擴展以及公共衛生重點轉變的影響。臨床開發正超越​​傳統的多醣體疫苗策略，結合疫苗和蛋白質次單元平台能夠提供更持久的保護效力，並適用於不同年齡層。同時，監管流程也在日趨成熟，能夠在疫情爆發期間快速審查疫苗，並促進研發人員、監管機構和公共衛生機構之間更緊密的合作。這些進展凸顯了整合策略的重要性，這些策略涵蓋臨床開發、生產規模化、供應鏈穩定性以及與支付方的合作。

科學突破、監管柔軟性和採購創新如何協同加速腦膜炎雙球菌疫苗計畫的能力和應對力。

近期技術和政策的變革正在改變腦膜炎雙球菌疫苗的研發、生產和供應方式。分子抗原設計和偶聯化學的進步使得候選疫苗能夠覆蓋更廣泛的血清型，並提高免疫抗原性。同時，佐劑科學和蛋白質工程也拓展了誘導各年齡層產生強效免疫反應的工具。這些科學進步與生產技術的創新相輔相成，例如模組化和一次性使用系統，這些技術縮短了前置作業時間，並實現了區域範圍內的靈活生產。

評估 2025 年關稅變化對製造選擇、籌資策略、供應鏈韌性和臨床供應物流的多方面影響。

2025年關稅調整的實施對腦膜炎雙球菌疫苗生態系統產生了多方面的影響，直接和間接地影響供應鏈、生產決策和籌資策略。關稅推高了進口原料（包括特殊試劑、一次性耗材和成品疫苗）的成本，促使生產商和採購商重新評估籌資策略。為此，一些生產商正在擴大其區域製造地或與供應商談判長期契約，以保護其業務免受關稅波動的影響。此類調整往往有利於擁有整合供應鏈和有資金投資本地生產能力的企業。

透過分析每種疫苗類型、年齡層、配方、分銷管道、最終用戶和適應症的需求促進因素及其臨床和商業性影響，我們可以幫助制定有針對性的策略。

為了深入了解市場，有必要專注於影響需求趨勢、臨床策略和商業化路徑的幾個細分領域。我們將根據疫苗類型，分析結合疫苗、多醣體疫苗和蛋白質次單元疫苗的市場格局。每種疫苗都有不同的免疫學特性，對目標族群的適用性也各不相同。結合疫苗因其免疫記憶效應以及在兒童和青少年常規免疫接種計劃中的效用而備受青睞。同時，多醣體製劑在應對特定集體爆發或作為補充手段方面仍可能保持其重要性。蛋白質次單元疫苗候選產品因其廣泛的交叉保護作用和更好的耐受性而備受關注，有望擴大其在成人和老年人群中的應用。

本研究探討了世界各地不同的流行病學情況、基礎設施成熟度和採購慣例如何影響疫苗的選擇、供應和能力優先排序。

區域趨勢對腦膜炎雙球菌疫苗的臨床優先事項、採購行為和營運需求有顯著影響。在美洲，監測能力和已建立的免疫規劃推動了對常規免疫接種計劃的持續需求，但零星疫情和旅行相關暴露仍然會造成一些地區緊急需求。這些地區的醫療衛生系統強調整合採購機制以及國家免疫規劃與地方採購負責人之間的協調。許多地區完善的低溫運輸基礎設施和較高的疫苗接種率有利於多劑次和單劑次疫苗的推廣，但仍有差異，需要製定因地制宜的分發策略。

分析競爭格局，其中科學差異化、製造靈活性和戰略夥伴關係決定產品准入和長期專案成功。

腦膜炎球菌疫苗領域的競爭動態由成熟的疫苗生產商、新興生物技術公司、契約製造和專業服務供應商共同構成​​。成熟的生產商憑藉其可靠的臨床記錄、廣泛的監管核准和成熟的生產線保持優勢，而新參與企業通常透過抗原創新、新型佐劑或靈活的生產能力來脫穎而出。策略夥伴關係和授權協議是加速獲取互補能力（例如結合技術和區域填充和包裝能力）的關鍵途徑，從而加快有前景的候選疫苗上市速度。

為製造商、政策制定者和供應鏈領導者制定明確且優先的行動方案，將科學進步轉化為擴充性、有韌性和公平的疫苗取得途徑。

行業領導者應採取一系列優先行動，將科學進步轉化為具有韌性和可及性的免疫接種計劃。首先，將供應鏈風險評估納入早期產品規劃，以識別關鍵投入和上游工程中的薄弱環節，並在策略上適宜的情況下尋求多元化和本地化生產。其次，透過減少對低溫運輸的依賴，並設計便於在兒童、青少年、成人和老年人等不同人群中給藥的製劑和劑型，使臨床開發適應最終用戶的實際情況。第三，與監管機構和公共衛生機構建立積極的合作關係，以簡化應對感染疾病疫情的核准流程，並確保可預測的採購承諾。

一項高度透明且嚴謹的混合方法研究，將與專家的初步訪談與系統的二次文獻綜述相結合，得出了檢驗且可操作的見解。

本分析的調查方法確保了嚴謹的證據基礎，具體做法是將結構化的原始研究與對同行評審文獻、監管文件和公開監測報告的系統性回顧相結合。原始研究包括對免疫專案管理人員、臨床研究人員、生產專家和採購負責人進行定性訪談，以了解實際情況和策略重點。二手資料包括科學文章、監管指導文件、臨床試驗註冊資訊和技術報告，這些資料提供了有關產品特性、安全性概況和實施注意事項的資訊。

科學創新與營運韌性的融合，為透過有針對性的疫苗接種策略持續減少腦膜炎雙球菌病菌感染奠定了基礎。

總之，由於技術創新、政策框架的演變以及供應和採購方面的營運變革，腦膜炎雙球菌疫苗的現狀正處於一個轉折點。結合疫苗技術、蛋白質次單元和生產方法的科學進步正在創造新的選擇，以更好地滿足不同年齡層和使用情境的需求。同時，不斷完善的政策和實驗性的採購措施使得應對集體爆發的措施更加靈活，並提高了公共衛生目標與商業性獎勵的契合度。這些因素共同凸顯了整合臨床卓越性、供應鏈韌性和相關人員合作的綜合策略的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 腦膜炎雙球菌疫苗市場：依疫苗類型分類

  • 組合型
  • 多醣
  • 蛋白質次單元

第9章 腦膜炎雙球菌疫苗市場：依年齡層別分類

  • 青年
  • 成人版
  • 老年人
  • 兒童

第10章：以劑型分類的腦膜炎雙球菌疫苗市場

  • 多次給藥
  • 單一劑量

第11章 腦膜炎雙球菌疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 腦膜炎雙球菌疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構
  • 疫苗接種中心

第13章 腦膜炎雙球菌疫苗市場：依適應症分類

  • 應對集體爆發
  • 常規疫苗接種
  • 旅行者疫苗接種

第14章 腦膜炎雙球菌疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 腦膜炎雙球菌疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 腦膜炎雙球菌疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國腦膜炎雙球菌疫苗市場

第18章：中國腦膜炎雙球菌疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bharat Biotech Ltd.
  • Bio-Med Private Ltd
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PT Bio Farma
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Taj Pharmaceuticals Limited
Product Code: MRR-430D42AA101A

The Meningococcal Vaccines Market was valued at USD 6.60 billion in 2025 and is projected to grow to USD 7.16 billion in 2026, with a CAGR of 11.02%, reaching USD 13.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.60 billion
Estimated Year [2026] USD 7.16 billion
Forecast Year [2032] USD 13.74 billion
CAGR (%) 11.02%

Contextualizing the evolving public health, clinical, and technological landscape that is reshaping strategic priorities for meningococcal vaccine stakeholders

The global landscape for meningococcal vaccines has entered a pivotal phase, shaped by advances in antigen design, expanded immunization recommendations, and evolving public health priorities. Clinical development has broadened beyond traditional polysaccharide approaches, with conjugate and protein subunit platforms offering improved durability of protection and suitability across diverse age groups. Concurrently, regulatory pathways have matured to accommodate accelerated reviews in outbreak contexts, prompting closer collaboration among developers, regulators, and public health agencies. These dynamics have elevated the importance of integrated strategies that span clinical development, manufacturing scale-up, supply chain security, and payer engagement.

As stakeholders reassess their long-term strategies, they must balance clinical performance with real-world delivery challenges. Vaccine developers are increasingly focused on attributes beyond efficacy, including thermostability, presentation formats that facilitate mass campaigns or routine schedules, and formulations designed for single-dose logistics. Health systems and immunization programs are prioritizing predictable supply and flexible procurement instruments, while research institutions emphasize surveillance to detect serogroup shifts. Together, these elements create a complex operational environment where cross-disciplinary coordination is essential for translating scientific progress into measurable reductions in meningococcal disease burden.

How scientific breakthroughs, regulatory agility, and procurement innovations are collectively accelerating capability and responsiveness in meningococcal vaccine programs

Recent technological and policy shifts are transforming how meningococcal vaccines are developed, manufactured, and delivered. Advances in molecular antigen design and conjugation chemistry have enabled candidates with broader serogroup coverage and improved immunogenicity, while adjuvant science and protein engineering have expanded the toolkit for eliciting robust immune responses across age cohorts. These scientific strides are complemented by innovations in manufacturing technologies, such as modular and single-use systems, which reduce lead times and support flexible production at regional scales.

On the policy front, public health authorities are increasingly adopting adaptive immunization policies informed by enhanced epidemiologic surveillance and modeling. This has shifted attention toward tailored strategies that consider local serogroup prevalence, population immunity profiles, and risk factors such as travel and mass gatherings. Simultaneously, procurement mechanisms are evolving; pooled purchasing, long-term purchase agreements, and advance market commitments are gaining traction as instruments for stabilizing supply and encouraging investment in capacity. Taken together, these transformative shifts are lowering technical and operational barriers, creating new opportunities to expand coverage and respond more nimbly to outbreak pressures.

Assessing the multifaceted implications of 2025 tariff changes on manufacturing choices, procurement strategies, supply chain resilience, and clinical supply logistics

The introduction of tariff adjustments in 2025 has had multifaceted implications for the meningococcal vaccine ecosystem, with direct and indirect effects on supply chains, manufacturing decisions, and procurement strategies. Tariffs raise the cost of imported inputs such as specialized reagents, single-use consumables, and finished vaccine shipments, prompting manufacturers and purchasers to reassess sourcing strategies. In response, some producers are expanding regional manufacturing footprints or negotiating longer-term supplier agreements to insulate operations from tariff volatility. Such adjustments tend to favor organizations with integrated supply chains or the capital to invest in localized capacity.

Moreover, tariffs influence the calculus of public-sector procurement. Health authorities and global partners reassess total landed costs and may adjust procurement schedules or prioritize domestically produced options when feasible. These dynamics also affect clinical trial supply logistics, where import duties on investigational materials can increase operational complexity. Importantly, tariffs have prompted closer collaboration between manufacturers and policymakers to design mitigation strategies, including tariff exemptions for essential health commodities, harmonized classification of vaccine components, and support for scaling regional fill-and-finish capabilities. While tariffs create short-term cost pressures, they also catalyze structural shifts in supply chain resilience and localization strategies that stakeholders can leverage to reduce future disruption risks.

Dissecting demand drivers and clinical-commercial implications across vaccine type, age cohort, formulation, distribution channel, end user, and indication to inform targeted strategies

A granular understanding of the market requires attention to several segmentation dimensions that affect demand dynamics, clinical strategy, and commercialization pathways. Based on Vaccine Type, the landscape is studied across Conjugate, Polysaccharide, and Protein Subunit approaches, each offering distinct immunological profiles and suitability for target populations. Conjugate vaccines continue to be favored for their immunological memory and utility in routine pediatric and adolescent schedules, while polysaccharide formulations may retain relevance for specific outbreak responses or as complementary tools. Protein subunit candidates are attracting interest where broad cross-protection and improved tolerability support expanded use in adults and older age groups.

Based on Age Group, analysis covers Adolescent, Adult, Geriatric, and Pediatric cohorts, recognizing that immunization strategies and clinical endpoints vary by life stage. Pediatric programs emphasize early-life protection and integration with routine schedules, adolescents represent a key group for catch-up and school-based campaigns, adults and geriatric populations require tailored immunogenicity and safety assessments, and travelers or occupational groups create targeted demand. Based on Formulation, the landscape examines Multi Dose and Single Dose presentations, with single-dose formats enhancing campaign efficiency and multi-dose vials offering cost advantages but requiring careful cold-chain and safety safeguards. Based on Distribution Channel, the study considers Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways, acknowledging shifting patient behaviors, digital prescribing trends, and the role of hospital systems in centralized immunization delivery. Based on End User, focus areas include Clinics, Hospitals, Research Institutes, and Vaccination Centers, each with distinct procurement practices, storage capabilities, and administration workflows. Based on Indication, the market is examined across Outbreak Response, Routine Prophylactic, and Traveler Immunization use cases, which guide product selection, regulatory obligations, and deployment timelines. Together, these segmentation lenses provide a nuanced framework for aligning clinical development priorities, commercialization strategies, and public health planning.

Exploring how distinct epidemiology, infrastructure maturity, and procurement practices across global regions influence vaccine selection, delivery, and capacity priorities

Regional dynamics materially shape clinical priorities, procurement behaviors, and operational requirements for meningococcal vaccines. In the Americas, surveillance capacity and established immunization programs drive consistent demand for routine schedules, while episodic outbreaks and travel-related exposures continue to create pockets of urgent need. Health systems in this region place emphasis on integrated procurement mechanisms and coordination between national immunization programs and subnational purchasers. Cold-chain infrastructure and high vaccination coverage in many settings facilitate deployment of both multi-dose and single-dose formats, yet disparities remain that require tailored distribution strategies.

Europe, Middle East & Africa exhibits wide heterogeneity: high-income parts of Europe maintain rigorous vaccine monitoring and policy processes that prioritize long-term protection, whereas regions within the Middle East and Africa contend with variable surveillance infrastructure, lower baseline coverage in some areas, and periodic large-scale outbreaks that necessitate rapid mass vaccination responses. Capacity building for laboratory confirmation and serogroup surveillance is a priority across several jurisdictions. The Asia-Pacific region presents a combination of large-scale routine immunization platforms, growing domestic manufacturing ambitions, and diverse epidemiologic profiles. Urban concentration and increasing travel create ongoing demand for traveler immunization, while investments in regional manufacturing and regulatory harmonization are enhancing supply security. Collectively, these regional patterns inform how stakeholders prioritize product portfolios, manufacturing investments, and public-private collaboration.

Mapping the competitive landscape where scientific differentiation, manufacturing agility, and strategic partnerships determine product access and long-term program success

Competitive dynamics in the meningococcal vaccine arena are shaped by a mixture of established vaccine manufacturers, emerging biotechnology firms, contract manufacturers, and specialized service providers. Incumbent manufacturers maintain advantages through proven clinical track records, broad regulatory approvals, and established production lines, while newer entrants frequently differentiate on antigen innovation, novel adjuvants, or manufacturing agility. Strategic partnerships and licensing arrangements have become a primary vehicle for accelerating access to complementary capabilities, such as conjugation expertise or regional fill-and-finish capacity, enabling faster route-to-market for promising candidates.

In parallel, contract manufacturing organizations and fill-and-finish specialists play an increasingly strategic role by offering scalable, geographically distributed capacity that can mitigate single-point failures. Collaboration between commercial teams and public health purchasers is also evolving; outcomes-based contracting, long-term supply agreements, and coordinated technology transfers are mechanisms being used to secure sustained access. Finally, alliances between academic researchers and industry accelerate translational work, particularly where novel protein subunit approaches require iterative clinical evaluation. Overall, organizations that combine scientific differentiation with flexible manufacturing, robust regulatory planning, and proactive stakeholder engagement are positioned to capture the most durable value.

Clear, prioritized actions for manufacturers, policymakers, and supply chain leaders to convert scientific progress into scalable, resilient, and equitable vaccine access

Industry leaders should adopt a prioritized set of actions to convert scientific advances into resilient, accessible immunization programs. First, integrate supply chain risk assessments into early product planning to identify critical inputs and upstream vulnerabilities, then pursue diversification or localized production where strategic. Second, align clinical development with end-user operational realities by designing formulations and delivery formats that reduce cold-chain reliance and facilitate administration across pediatric, adolescent, adult, and geriatric settings. Third, cultivate proactive engagement with regulators and public health agencies to streamline approval pathways for outbreak responses and to secure predictable procurement commitments.

Additionally, pursue scalable manufacturing models that leverage modular facilities and contract partners to accelerate capacity expansion without overextending capital commitments. Strengthen surveillance partnerships with public health laboratories and academic centers to detect serogroup shifts and to inform adaptive immunization strategies. Finally, invest in evidence generation that demonstrates real-world effectiveness, safety across age cohorts, and health economic value to support inclusion in immunization schedules and to facilitate payer negotiations. By executing these priorities in parallel, organizations can improve their ability to respond to outbreaks, expand routine protection, and sustain reliable supply.

A transparent and rigorous mixed-methods research approach combining primary expert interviews and systematic secondary review to produce validated, actionable insights

The research methodology underpinning this analysis combined structured primary research with systematic review of peer-reviewed literature, regulatory documents, and publicly available surveillance reports to ensure a rigorous evidence base. Primary research included qualitative interviews with immunization program leaders, clinical investigators, manufacturing experts, and procurement specialists to capture operational realities and strategic priorities. Secondary sources comprised scientific publications, regulatory guidance documents, clinical trial registries, and technical reports that inform product attributes, safety profiles, and implementation considerations.

Data synthesis followed a transparent process: findings from interviews and document reviews were triangulated to identify consistent themes and to highlight areas of divergence. Quality assurance steps included source validation, cross-referencing of clinical and regulatory data, and expert review by independent advisors with domain experience in vaccinology, public health policy, and pharmaceutical manufacturing. Throughout, ethical standards and confidentiality protocols were maintained for interview subjects, and analytical assumptions were explicitly documented to ensure reproducibility of insights and to support evidence-based decision-making.

Converging scientific innovation and operational resilience form the foundation for sustained progress in reducing meningococcal disease through targeted vaccine strategies

In summary, the meningococcal vaccine landscape is at an inflection point driven by technical innovation, evolving policy frameworks, and operational shifts in supply and procurement. Scientific advances in conjugate technologies, protein subunits, and manufacturing methodologies are creating new options that better match the needs of diverse age cohorts and use cases. At the same time, policy evolution and procurement experimentation are enabling more adaptive responses to outbreaks and improving alignment between public health goals and commercial incentives. These converging factors underscore the importance of integrated strategies that combine clinical excellence with supply chain resilience and stakeholder collaboration.

Going forward, success will hinge on the ability of stakeholders to translate immunologic improvements into products that are logistically feasible and economically viable for routine programs and emergency responses. Investments in regional capacity, strategic partnerships, and surveillance infrastructure will be critical to sustaining long-term access and ensuring that clinical gains translate into measurable reductions in disease burden. For decision-makers, the imperative is to pursue coordinated planning across development, manufacturing, regulation, and delivery so that innovations reach populations in need with speed, reliability, and equity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Meningococcal Vaccines Market, by Vaccine Type

  • 8.1. Conjugate
  • 8.2. Polysaccharide
  • 8.3. Protein Subunit

9. Meningococcal Vaccines Market, by Age Group

  • 9.1. Adolescent
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Meningococcal Vaccines Market, by Formulation

  • 10.1. Multi Dose
  • 10.2. Single Dose

11. Meningococcal Vaccines Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Meningococcal Vaccines Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes
  • 12.4. Vaccination Centers

13. Meningococcal Vaccines Market, by Indication

  • 13.1. Outbreak Response
  • 13.2. Routine Prophylactic
  • 13.3. Traveler Immunization

14. Meningococcal Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Meningococcal Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Meningococcal Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Meningococcal Vaccines Market

18. China Meningococcal Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Astellas Pharma Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. Bharat Biotech Ltd.
  • 19.8. Bio-Med Private Ltd
  • 19.9. GlaxoSmithKline PLC
  • 19.10. Incepta Pharmaceuticals Ltd.
  • 19.11. Merck & Co., Inc.
  • 19.12. Novartis AG
  • 19.13. Pfizer Inc.
  • 19.14. PT Bio Farma
  • 19.15. Sanofi S.A.
  • 19.16. Serum Institute of India Pvt. Ltd.
  • 19.17. Taj Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)